


Ordering Information

Balloon length (mm)	Balloon Diameter (mm)						
	1.50	2.00	2.50	2.75	3.00	3.50	4.00
10	PWR-1510	PWR-2010	PWR-2510	-	PWR-3010	PWR-3510	PWR-4010
15	PWR-1515	PWR-2015	PWR-2515	-	PWR-3015	PWR-3515	PWR-4015
20	PWR-1520	PWR-2020	PWR-2520	PWR-2720	PWR-3020	PWR-3520	PWR-4020
25	PWR-1525	PWR-2025	PWR-2525	-	PWR-3025	PWR-3525	PWR-4025
30	PWR-1530	PWR-2030	PWR-2530	-	PWR-3030	PWR-3530	PWR-4030

Compliance Table

Pressure (atm)	Balloon Size (mm)						
	1.50	2.00	2.50	2.75	3.00	3.50	4.00
5	1.47	1.97	2.47	2.72	2.97	3.47	3.97
6 Nominal	1.50	2.00	2.50	2.75	3.00	3.50	4.00
7	1.53	2.03	2.53	2.78	3.03	3.53	4.03
8	1.56	2.06	2.56	2.81	3.06	3.56	4.06
9	1.59	2.09	2.59	2.84	3.09	3.59	4.09
10	1.62	2.12	2.62	2.87	3.12	3.62	4.12
11	1.65	2.15	2.65	2.90	3.15	3.65	4.15
12	1.68	2.18	2.68	2.93	3.18	3.68	4.18
13	1.71	2.21	2.71	2.96	3.21	3.71	4.21
14 Rated Burst	1.74	2.24	2.74	2.99	3.24	3.74	4.24



- A. Flexible tip section with smooth transition and short bonding to increase flexibility gradually.
- B. Semi-compliant Polyamide Elastomer balloon material combined with Slip-X™ hydrophilic coating for enhanced crossability.
- C. Power stylet transition in the middle shaft to provide a smoother force transmission from the proximal to the distal shaft.
- D. PTFE coated 2.0F hypotube for improved pushability.

POWERLINE™
PTCA CATHETER

Take the fast track to superior patient outcomes

Powerline™ PTCA catheter is CE approved.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.

Powerline, BioMatrix, Biolimus A9, Slip-X and Improving Lives Through Medical Innovation are trademarks of Biosensors International Group, Ltd.

All cited trademarks are the property of their respective owners.

Not available for sale in the United States and certain other countries
© 2014 Biosensors International Group, Ltd. All rights reserved

www.biosensors.com

Pre-dilatation

– can facilitate procedural success to optimize DES patient outcomes

Drug-eluting stents (DES) have defined a new era in the successful treatment of coronary artery disease. However, like any therapy, DES results are not always what are predicted or expected.

Stent placement alone however does not guarantee the best outcome. Unless the stent is optimally deployed with full lesion coverage, full expansion and good apposition to the vessel wall, there remains a risk of complications such as late stent thrombosis*.

Pre-dilatation can optimize stent deployment to achieve the full benefits of DES therapy, especially where it is vital to ensure positive stent apposition and uniform absorption of drug within the treated lesion.

Push – Track – Cross


– achieving the right balance to meet the clinical need

Powerline's advanced catheter technology is designed to offer the right balance of **PUSH**, **TRACK** and **CROSS** to ensure optimal balloon placement and expansion:

A PUSH
The PTFE-coated hypotube in combination with the power stylet transition in the middle shaft provides the right balance between pushability and trackability offering a smoother force transmission from the proximal to distal portion of the catheter shaft.

B TRACK
The combination of the Slip-X™ hydrophilic coating and the flexible distal shaft ensure excellent trackability and crossability for complex lesions or tortuous anatomy.

C CROSS
The flexible low profile tip section with smooth transition and short bonding offers a gradual increase towards the balloon to facilitate lesion entry. Powerline's advanced MultiPleat folding technology is designed to offer exceptional lesion crossability and uniform balloon expansion as well as excellent balloon re-wrap and re-cross properties for treating challenging lesions.



Powerline™ & BioMatrix™

– designed to optimize your DES patient outcomes

The combination of Powerline's advanced catheter technology to pre-dilate the lesion and the BioMatrix drug-eluting coronary stent system, developed for improved healing and long-term safety, are designed to optimize your DES patient outcomes.

BioMatrix offers the unique combination of a proprietary anti-restenotic drug, Biolimus A9™, a biodegradable poly-lactic acid polymer (PLA), and an advanced, highly flexible stent designed for enhanced deliverability.

* Cheneau Study: Edouard Cheneau, et al. "Predictors of Subacute Thrombosis. Results of a Systematic Intravascular Ultrasound Study." Circulation 2003; 108: 43-47